American Journal of Hematology · 2005 · 134 citations · 17 references
MedicineHematologyHematopathologyIron Metabolism DisordersTransfusion MedicineAnemiaIron DeficiencyIron Deficiency DisordersIron MetabolismSickle Cell DiseaseTransfusional Iron OverloadBlood Transfusion TherapyChronic Transfusion SupportIron Overload PathophysiologyLiver Iron Concentration AssessmentLiver Iron Concentration MeasurementSickle Cell AnemiaThalassemia TransfusionTransfusion-related Iron Overload
Although it is life saving, transfusion therapy has resulted in the majority of sickle cell anemia and thalassemia patients being at risk for hemosiderosis-induced organ damage. It is unknown whether the complications of iron overload are affected by the underlying disease. In order to address this problem, we compared the prevalence of organ dysfunction in both groups of patients receiving chronic transfusion therapy (beta thalassemia, N = 30; sickle cell anemia, N = 43). Both groups had similar quantitative liver iron. Thalassemia patients had greater cardiac disease (20% vs. 0%), growth failure (27% vs. 9%), and endocrine failure (37% vs. 0%). The strongest predictors of combined endocrine and cardiac disease in multivariate analysis were duration of chronic transfusion (P = 0.03) and diagnosis (P = 0.03). Quantitative liver iron concentration on a single liver biopsy was not predictive of cardiac or endocrine injury. Viral hepatitis is the strongest predictor of hepatocellular damage (P = 0.009), while the development of liver fibrosis is more closely related to liver iron concentration (P = 0.04). In conclusion, sickle cell anemia and thalassemia differ in the prevalence of organ injury. This difference is related to the duration of iron exposure and the specific hemoglobinopathy. A prospective study with a larger number of subjects is needed to confirm the relationships between specific diagnosis, liver iron concentration over time, and organ dysfunction.
17
Classification of chronic hepatitis: Diagnosis, grading and staging
Valeer Desmet, Michael A. Gerber, Jay H. Hoofnagle et al. · Hepatology · 1994 · 2.6K citations
Robert J. Adams, Lewis L. Hsu, Elliott Vichinsky et al. · New England Journal of Medicine · 1998 · 1.9K citations · Full text
Medicine, Hematology, Pediatrics +10
Iron-Chelating Therapy and the Treatment of Thalassemia
Nancy F. Olivieri, Gary M. Brittenham · Blood · 1997 · 1.1K citations · Full text
Survival in Medically Treated Patients with Homozygous β-Thalassemia
Nancy F. Olivieri, David G. Nathan, James H. MacMillan et al. · New England Journal of Medicine · 1994 · 864 citations · Full text
Medicine, Cardiology, Hematology +15